Milestones & Legacy
2025
Yesafili, biosimilar aflibercept, becomes the 10th biosimilar to be commercialized worldwide by Biocon Biologics.
Yesintek, biosimilar ustekinumab, receives marketing approval in the EU, UK and Japan.
Kirsty is approved by the U.S. FDA as the first and only interchangeable rapid-acting insulin aspart.
Biosimilar versions of denosumab for treating osteoporosis and cancer-related bone conditions are approved in the U.S., EU and UK.
2024
Biocon Biologics emerges as a fully integrated global biosimilars leader, and crosses the USD 1 billion revenue milestone.
Yesafili is approved by the U.S. FDA as the first interchangeable biosimilar aflibercept.
Yesintek, biosimilar ustekinumab, is approved in the U.S.
2023
Biocon Biologics successfully integrates acquired Viatris business globally, expanding commercial footprint to 120+ markets worldwide.
Yesafili (aflibercept) receives marketing approval in the EU.
2022
Biocon Biologics acquires Viatris’ global biosimilars business in a multi-billion-dollar deal.
2021
Semglee, biosimilar Insulin Glargine, receives a historic U.S. approval as the world’s first ‘interchangeable’ biosimilar product.
Kirsty (insulin aspart) and Abevmy (bevacizumab) receive marketing approvals in Europe.
2020
Nepexto (etanercept) receives marketing approval in Europe.
2019
Biocon’s biosimilars business is consolidated under an independent entity – Biocon Biologics Limited – with its dedicated management.
2018
Fulphila becomes the first biosimilar pegfilgrastim to be approved in the U.S.
Ogivri (trastuzumab), Fulphila (pegfilgrastim), Semglee (insulin glargine), and Hulio (adalimumab) receive marketing approvals in the EU.
2017
Ogivri becomes the first biosimilar trastuzumab to be approved in the U.S.
2016
Biocon becomes the first company from India to have a biosimilar approved and commercialized in Japan following the regulatory nod to insulin glargine.
2015
Biocon inaugurates a 100,000- square- foot facility for manufacturing new-generation, patient-friendly insulin devices in India.
2014
Biocon launches the world’s first approved biosimilar version of trastuzumab in India.
2013
Biocon expands an existing biosimilars partnership with Viatris (formerly Mylan) to develop a portfolio of insulin analogs.
Biocon commercializes ALZUMAb® (Itolizumab), the world’s first novel anti-CD6 monoclonal antibody, in India for the treatment of psoriasis.
2012
Biocon Research Centre, a 200,000-square-foot, state-of-the-art facility, is inaugurated to foster a culture of innovation and frontier research.
2009
Biocon partners with Viatris (formerly Mylan) to co-develop high-value biosimilars for oncology and autoimmune indications, marking one of the earliest partnerships in the global biosimilars space.
2007
Biocon divests legacy enzymes business to Novozymes for USD 115 million.
2006
Biocon Park, India’s largest integrated biotechnology hub spread across 90 acres, is inaugurated in India by former President of India Dr A.P.J. Abdul Kalam.
Biocon commercializes India’s first indigenously produced novel mAb, BIOMAb EGFR® (Nimotuzumab) for the treatment of head and neck cancer.
2004
Biocon is the first and only company in the world to commercialize a Pichia pastoris-derived recombinant human insulin.
A hugely successful IPO makes Biocon the second Indian company ever to cross the USD 1 billion mark on the first day of listing.
2002
Biocon forays into development of antibodies using mammalian cell-based expression systems through a joint venture with a Cuban biotechnology company.
2000
Biocon is among the first Indian companies to envision a biosimilars-led future, initiating efforts to build capabilities for developing affordable, high-quality biosimilar therapies.
PlaFractor™, its patented fermentation reactor, enables Biocon to become the first company to produce the immunosuppressant, mycophenolate mofetil, using this technology.
1993
Biocon becomes the first life sciences company out of India to receive ISO 9001 certification from RWTUV, Germany, for its R&D and manufacturing facilities.
1984-89
An R&D division focused on solid state fermentation technology is established to drive research in novel enzymes. Within 5 years, Biocon begins producing enzymes for Unilever’s food businesses.
1983
A state-of-the-art integrated campus, spread over 20 acres, is commissioned to house Biocon’s manufacturing facilities and corporate office.
1979
Biocon exports papain, a plant enzyme derived from papaya, to U.S. and Europe, signalling the company’s ambition to produce high-quality, world class products in India for global markets.
1978
Biocon India Pvt. Ltd. is incorporated as a joint venture between Kiran Mazumdar-Shaw and Biocon Biochemicals Ltd. Ireland.
